SL01 Mining Marine Microorganisms Provides Mechanistically-Unique Drug Leads for the Treatment of Cancer

William FENICAL

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego

Marine microorganisms, and in particular marine actinomycete bacteria, are a genetically-unique and chemically-rich source for the discovery of new drug leads [1]. The development of novel isolation and culture methods has allowed access to a variety of previously uncultured strains that now form the foundation for innovative cancer drug discovery efforts [2]. Examining this new chemical source and coupling it with a program to identify new intracellular protein targets has provided several new and unpredicted pathways that can be exploited for cancer treatment [3]. Cytotoxic marine microbial metabolites such as the ammosamides, marinopyrroles, napyradiomycins, seriniquinones, and most recently chlorizidine, show binding affinity to a diversity of new protein targets, illustrating that a wealth of new approaches exist to treating various cancers [4-8]. These and more recent discoveries will form the content of this presentation.

References:

[1] Jensen, P.R., Fenical, W. 2005. Marine actinomycete bacteria, developing a new resource for drug discovery. *Nature Chem Biol*, 2, 666-673.

[2] Jensen, P.R., Williams, P.G., Oh, D-C, Zeigler, L., Fenical, W. 2007. Species-specific secondary metabolite production in marine actinomycetes of the genus *Salinispora*. *Appl Environ Microbiol*, 73(4), 1146–1152.

[3] Alexander, M.D. *et al.* 2006. A central strategy for converting natural products into fluorescent probes. *ChemBioChem*, 7, 409–416.

[4] Hughes, C.C., MacMillan, J.B., Gaudêncio, S.P., Jensen, P.R., Fenical, W, La Clair, J.J. 2009. Ammosamides A and B Target Myosin. *Angew Chem Int Ed*, 48, 728-732.

[5] Hughes, C.C., Yang, Y-L, Liu, W-T, Dorrestein, P.C, La Clair, J.J., Fenical W. 2010. Marinopyrrole A target elucidation by acyl dye transfer. *J Am Chem Soc*, 131, 12094–12096.

[6] Trzoss L, Fukuda T, Costa-Lotufo LT, Jimenez PT, Ghassemian M, La Clair JJ, Fenical W. 2014. Seriniquinone illustrates melanoma selectivity via induction of autophagocytosis through dermcidin deactivation. *Proc Nat Acad Sci US*, 111, 14687–14692.

[7] Farnaes, L, La Clair, J.J., Fenical, W. 2014. Napyradiomycins target the Hsp90 paralogue Grp94. *Org Biomol Chem*, 12, 414-420.

[8] Álvarez-Micó, X., Rocha, D.D., Guimarães, L.A., Ambrose, A., Chapman, E., Costa-Lotufo[,] L.V., La Clair, J.J., Fenical, W. 2015. Evaluation of the intracellular protein binding of the hybrid pyrroloisoindolone–dehydropyrrolizine alkaloid (-)-Chlorizidine A. *ChemBiochem*, in press.